(4-(4-aminophenyl)piperazin-1-yl)(cyclopropyl)methanone

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: (4-(4-aminophenyl)piperazin-1-yl)(cyclopropyl)methanone
• 英文别名: 4-[4-(Cyclopropylcarbonyl)-1-piperazinyl]aniline；[4-(4-aminophenyl)piperazin-1-yl]-cyclopropylmethanone
• 化学式: C₁₄H₁₉N₃O
• mdl: MFCD08165780
• 分子量: 245.324
• InChiKey: WTLKZCHODLBPMW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  49.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (4-(4-aminophenyl)piperazin-1-yl)(cyclopropyl)methanone 在 盐酸 、 sodium hydroxide 、 sodium nitrite 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 6.0h， 生成 (4-(4-((3-amino-4-nitrophenyl)thio)phenyl)piperazin-1-yl)(cyclopropyl)methanone
  参考文献：
  名称：

  [EN] THIOBENZIMIDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF
  [FR] DÉRIVÉ DE THIOBENZIMIDAZOLE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI ET UTILISATION ASSOCIÉE
  [KO] 티오벤즈이미다졸 유도체 또는 이의 약학적으로 허용가능한 염 및 이의 용도

  摘要：

  본 발명은 티오벤즈이미다졸 유도체 또는 이의 약학적으로 허용가능한 염 및 상기 유도체를 유효성분으로 포함하는 암 예방 또는 치료용 조성물 등에 관한 것으로서, 본 발명의 티오벤즈이미다졸 유도체는 암 세포에서 활성화되어 튜불린 중합 (tubulin polymerization)을 저해하며, 개체에 투여 시 암 세포 주기를 차단하고 세포사멸을 유도함으로써 세포 독성을 나타내는바, 암의 예방 또는 치료, 바람직하게는 HER-2 양성유방암 또는 삼중음성유방암의 예방 및 치료에 사용될 수 있다.

  公开号：

  WO2023191536A1

文献信息

• [EN] PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE<br/>[FR] DÉRIVÉ DE PYRIMIDO-PYRIMIDO-INDAZOLE
  申请人：BANYU PHARMA CO LTD

  公开号：WO2010098367A1

  公开（公告）日：2010-09-02

  The invention is to provide a novel anticancer agent or sensitizer for cancer chemotherapy or radiotherapy. A compound of a general formula (I): wherein A means an aryl group or a heteroaryl group, or a group of a formula (a):; R1 means a -(C=O)aOb(C1-C6)alkyl group, a -(C=O)aOb(C2-C6)alkenyl group, a -(C=O)aOb(C3-C6)cycloalkyl group, an aryl group or a heteroaryl group; R2 and R3 each mean a hydrogen atom, a halogen atom, a hydroxyl group, a carboxyl group, a -(C=O)aOb(C1-C6)alkyl group or a group of -(C=O)aN(R1e)R2e; R4 means a hydrogen atom or a (C1-C6)alkyl group, and the like have an excellent Wee1-kinase-inhibitory effect, and are therefore useful in the field of medicine, especially in the field of various cancer treatments.

  这项发明是为了提供一种新型的抗癌药物或增敏剂，用于癌症化疗或放疗。通式(I)的化合物：其中A表示芳基或杂环基，或者是式(a)的基团；R1表示-(C=O)aOb(C1-C6)烷基、-(C=O)aOb(C2-C6)烯基、-(C=O)aOb(C3-C6)环烷基、芳基或杂环基；R2和R3各自表示氢原子、卤素原子、羟基、羧基、-(C=O)aOb(C1-C6)烷基或-(C=O)aN(R1e)R2e的基团；R4表示氢原子或(C1-C6)烷基等，具有优异的Wee1激酶抑制作用，因此在医学领域特别是各种癌症治疗领域中非常有用。
• [EN] HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES<br/>[FR] COMPOSÉS À PETITES MOLÉCULES MIMÉTIQUES DES FACTEURS DE CROISSANCE HÉMATOPOÏÉTIQUE ET LEURS UTILISATIONS
  申请人：LIGAND PHARM INC

  公开号：WO2011046954A1

  公开（公告）日：2011-04-21

  The present embodiments relate to compounds with physiological effects, such as the activation of hematopoietic growth factor receptors. The present embodiments also relate to use of the compounds to treat a variety of conditions, diseases and ailments such as hematopoietic conditions and disorders.

  目前的实施例涉及具有生理效应的化合物，例如激活造血生长因子受体。目前的实施例还涉及利用这些化合物来治疗各种疾病、疾病和疾患，如造血状况和疾病。
• [EN] NOVEL KINASE INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DE KINASES
  申请人：ORIGENIS GMBH

  公开号：WO2014060113A1

  公开（公告）日：2014-04-24

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及一种具有公式（I）的新化合物，能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复的激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体。这些化合物在治疗多种疾病中发挥作用。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和激素相关疾病。
• [EN] 2, 6-DIAMINO-PYRIMIDIN- 5-YL-CARBOXAMIDES AS SYK OR JAK KINASES INHIBITORS<br/>[FR] 2, 6-DIAMINO-PYRIMIDIN- B-YL-CARBOXAMIDES SERVANT D'INHIBITEURS DE Syk KINASES ET DE JANUS KINASES
  申请人：PORTOLA PHARM INC

  公开号：WO2009145856A1

  公开（公告）日：2009-12-03

  The present invention is directed to compounds of formula I-II and pharmaceutically acceptable tautomers, salts, or stereoisomers thereof which are inhibitors of syk and/or JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition syk and/or JAK kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by syk and/or JAK kinase activity, such as cardiovascular disease, inflammatory disease, autoimmune disease and cell proliferative disorder, thrombosis, allergy, asthma, rheumatoid arthritis, leukemia, or non-Hodgkin's lymphoma.

  本发明涉及式I-II的化合物及其药学上可接受的互变异构体、盐或立体异构体，这些化合物是syk和/或JAK激酶的抑制剂。本发明还涉及用于制备这类化合物的中间体，制备这种化合物，含有这种化合物的药物组合物，抑制syk和/或JAK激酶活性的方法，抑制血小板聚集的方法，以及预防或治疗由syk和/或JAK激酶活性至少部分介导的多种疾病的方法，如心血管疾病、炎症性疾病、自身免疫疾病和细胞增殖障碍、血栓形成、过敏、哮喘、类风湿关节炎、白血病或非霍奇金淋巴瘤。
• [EN] PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS<br/>[FR] PYRAZOLO[4,3-D]PYRIMIDINES UTILES EN TANT QU'INHIBITEURS DE KINASES
  申请人：ORIGENIS GMBH

  公开号：WO2014060112A1

  公开（公告）日：2014-04-24

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及具有式（I）的新化合物，其能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复的激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体。这些化合物可用于治疗多种疾病。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和激素相关疾病。